Clinical Trial Update: A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating elenbecestat (E2609) in early Alzheimer's disease was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• elenbecestat (elenbecestat)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-02-03